tetano
Editor, Senior Moderator
Bull Cancer
. 2021 Apr 12;S0007-4551(21)00137-5.
doi: 10.1016/j.bulcan.2021.03.009. Online ahead of print.
[Vaccination against COVID-19 in patients with solid cancer: Review and point of view from a French oncology inter-group (CGO, TNCD, UNICANCER)]
[Article in French]
David Tougeron[SUP] 1 [/SUP], Barbara Seitz-Polski[SUP] 2 [/SUP], Maxime Hentzien[SUP] 3 [/SUP], Firouze Bani-Sadr[SUP] 3 [/SUP], Jean Bourhis[SUP] 4 [/SUP], Michel Ducreux[SUP] 5 [/SUP], S?bastien Gaujoux[SUP] 6 [/SUP], Philippe Gorphe[SUP] 7 [/SUP], Boris Guiu[SUP] 8 [/SUP], Anne Claire Hardy-Bessard[SUP] 9 [/SUP], Kh? Hoang Xuan[SUP] 10 [/SUP], Florence Huguet[SUP] 11 [/SUP], Thierry Lecomte[SUP] 12 [/SUP], Astrid Li?vre[SUP] 13 [/SUP], Christophe Louvet[SUP] 14 [/SUP], L?on Maggiori[SUP] 15 [/SUP], Pascale Mariani[SUP] 16 [/SUP], Pierre Michel[SUP] 17 [/SUP], Am?lie Servettaz[SUP] 3 [/SUP], Juliette Thariat[SUP] 18 [/SUP], Virginie Westeel[SUP] 19 [/SUP], Thomas Aparicio[SUP] 20 [/SUP], Jean Yves Blay[SUP] 21 [/SUP], Olivier Bouch?[SUP] 22 [/SUP], Th?saurus national de canc?rologie digestive (TNCD); r?seau de groupes coop?rateurs en oncologie (GCO); F?d?ration nationale des centres de lutte contre le cancer (UNICANCER); association de chirurgie h?pato-bilio-pancr?atique et transplantation (ACHBT); association de recherche sur les cancers gynecologiques-groupes d?investigateurs nationaux pour l??tude des cancers ovariens et du sein (ARCAGY-GINECO); F?d?ration francophone de canc?rologie digestive (FFCD), groupe coop?rateur multidisciplinaire en oncologie (GERCOR), groupe d?oncologie radioth?rapie t?te et cou-intergroupe ORL (GORTEC-Intergroupe ORL); intergroupe francophone de canc?rologie thoracique (IFCT); intergroupe coop?rateur de neuro-oncologie association des neuro-oncologues d?expression fran?aise (IGCNO-ANOCEF); Soci?t? fran?aise de chirurgie digestive (SFCD); Soci?t? fran?aise d?endoscopie digestive (SFED); Soci?t? fran?aise de radioth?rapie oncologique (SFRO); Soci?t? fran?aise de radiologie (SFR); Soci?t? nationale fran?aise de colo-proctologie (SNFCP); Soci?t? nationale fran?aise de gastroent?rologie (SNFGE)
Affiliations
Abstract
The COVID-19 pandemic has a major impact at all stages of cancer treatment. Risk of death from COVID-19 in patients treated for a cancer is high. COVID-19 vaccines represent a major issue to decrease the rate of severe forms of the COVID-19 cases and to maintain a normal cancer care. It is difficult to define the target population for vaccination due to the limited data available and the lack of vaccine doses available. It appears theoretically important to vaccinate patients with active cancer treatment or treated since less than three years, as well as their family circle. In France, patients actually defined at "high risk" for priority access to vaccination are those with a cancer treated by chemotherapy. A panel of experts recently defined another "very high-priority" population, which includes patients with curative or palliative first or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large lung volume, lymph nodes and/or of hematopoietic tissue. Ideally, it is best to vaccinate before cancer treatment. Despite the lack of published data, COVID-19 vaccines can also be performed during chemotherapy by avoiding periods of bone marrow aplasia and if possible, to do it in cancer care centers. It is necessary to implement cohorts with immunological and clinical monitoring of vaccinated cancer patients. To conclude, considering the current state of knowledge, the benefit-risk ratio strongly favours COVID-19 vaccination of all cancer patients.
Keywords: COVID-19; Cancers solides; Chemotherapy; Chimioth?rapie; Coronavirus; Radiotherapy; Radioth?rapie; Solid cancers; Vaccination.
. 2021 Apr 12;S0007-4551(21)00137-5.
doi: 10.1016/j.bulcan.2021.03.009. Online ahead of print.
[Vaccination against COVID-19 in patients with solid cancer: Review and point of view from a French oncology inter-group (CGO, TNCD, UNICANCER)]
[Article in French]
David Tougeron[SUP] 1 [/SUP], Barbara Seitz-Polski[SUP] 2 [/SUP], Maxime Hentzien[SUP] 3 [/SUP], Firouze Bani-Sadr[SUP] 3 [/SUP], Jean Bourhis[SUP] 4 [/SUP], Michel Ducreux[SUP] 5 [/SUP], S?bastien Gaujoux[SUP] 6 [/SUP], Philippe Gorphe[SUP] 7 [/SUP], Boris Guiu[SUP] 8 [/SUP], Anne Claire Hardy-Bessard[SUP] 9 [/SUP], Kh? Hoang Xuan[SUP] 10 [/SUP], Florence Huguet[SUP] 11 [/SUP], Thierry Lecomte[SUP] 12 [/SUP], Astrid Li?vre[SUP] 13 [/SUP], Christophe Louvet[SUP] 14 [/SUP], L?on Maggiori[SUP] 15 [/SUP], Pascale Mariani[SUP] 16 [/SUP], Pierre Michel[SUP] 17 [/SUP], Am?lie Servettaz[SUP] 3 [/SUP], Juliette Thariat[SUP] 18 [/SUP], Virginie Westeel[SUP] 19 [/SUP], Thomas Aparicio[SUP] 20 [/SUP], Jean Yves Blay[SUP] 21 [/SUP], Olivier Bouch?[SUP] 22 [/SUP], Th?saurus national de canc?rologie digestive (TNCD); r?seau de groupes coop?rateurs en oncologie (GCO); F?d?ration nationale des centres de lutte contre le cancer (UNICANCER); association de chirurgie h?pato-bilio-pancr?atique et transplantation (ACHBT); association de recherche sur les cancers gynecologiques-groupes d?investigateurs nationaux pour l??tude des cancers ovariens et du sein (ARCAGY-GINECO); F?d?ration francophone de canc?rologie digestive (FFCD), groupe coop?rateur multidisciplinaire en oncologie (GERCOR), groupe d?oncologie radioth?rapie t?te et cou-intergroupe ORL (GORTEC-Intergroupe ORL); intergroupe francophone de canc?rologie thoracique (IFCT); intergroupe coop?rateur de neuro-oncologie association des neuro-oncologues d?expression fran?aise (IGCNO-ANOCEF); Soci?t? fran?aise de chirurgie digestive (SFCD); Soci?t? fran?aise d?endoscopie digestive (SFED); Soci?t? fran?aise de radioth?rapie oncologique (SFRO); Soci?t? fran?aise de radiologie (SFR); Soci?t? nationale fran?aise de colo-proctologie (SNFCP); Soci?t? nationale fran?aise de gastroent?rologie (SNFGE)
Affiliations
- PMID: 33902918
- DOI: 10.1016/j.bulcan.2021.03.009
Abstract
The COVID-19 pandemic has a major impact at all stages of cancer treatment. Risk of death from COVID-19 in patients treated for a cancer is high. COVID-19 vaccines represent a major issue to decrease the rate of severe forms of the COVID-19 cases and to maintain a normal cancer care. It is difficult to define the target population for vaccination due to the limited data available and the lack of vaccine doses available. It appears theoretically important to vaccinate patients with active cancer treatment or treated since less than three years, as well as their family circle. In France, patients actually defined at "high risk" for priority access to vaccination are those with a cancer treated by chemotherapy. A panel of experts recently defined another "very high-priority" population, which includes patients with curative or palliative first or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large lung volume, lymph nodes and/or of hematopoietic tissue. Ideally, it is best to vaccinate before cancer treatment. Despite the lack of published data, COVID-19 vaccines can also be performed during chemotherapy by avoiding periods of bone marrow aplasia and if possible, to do it in cancer care centers. It is necessary to implement cohorts with immunological and clinical monitoring of vaccinated cancer patients. To conclude, considering the current state of knowledge, the benefit-risk ratio strongly favours COVID-19 vaccination of all cancer patients.
Keywords: COVID-19; Cancers solides; Chemotherapy; Chimioth?rapie; Coronavirus; Radiotherapy; Radioth?rapie; Solid cancers; Vaccination.